Publication: Koroner arter hastalarında plazma inkretin hormon düzeyleri ile metabolik sendrom kriterleri arasındaki ilişki
Abstract
Amaç: Metabolik sendrom (MetS), yüksek açlık plazma glikozu, abdominal obezite, yüksek kan basıncı, serumda yüksek trigliserid ve düĢük yüksek-yoğunluklu lipoprotein (HDL) seviyelerini içeren bir metabolik bozukluklar kümesidir. Kardiyovasküler hastalık ve erken ölüm riskini artırır. Ġnkretin hormonlar, özellikle Glukagon benzeri peptid-1 (GLP-1), gıda alımına yanıt olarak bağırsaktan salgılanır ve insülin salgılanmasını artırır. Ayrıca, gıda alımı, kan basıncı ve lipid metabolizması üzerinde çok faktörlü etkilere sahiptir. Bu çalıĢmanın amacı, serum GLP-1 hormonu ile MetS kriterleri arasındaki iliĢkiyi araĢtırmaktır.Gereç ve yöntem: Bu çalıĢmaya koroner anjiyografi yapılan yirmi yedi hasta dahil edildi. Vücut kitle indeksi (VKĠ) gibi antropometrik ölçümler ve diğer gerekli veriler anketler ile toplanıldı. Serum örneklerindeki glikoz, insülin, kolesterol, trigliserid, HDL ve düĢük-yoğunluklu lipoprotein (LDL) düzeyleri otoanalizör kullanılarak ölçüldü. Plazma GLP-1 konsantrasyonunun ölçümü ELISA metodu ile yapıldı. Ġstatistiksel analiz SPSS kullanılarak gerçekleĢtirildi.Bulgular: VKĠ’i < 30 kg/ m² olanlara göre, VKĠ’i ≥ 30 kg/ m² olan hastalarda, insülin direnç indeksi (HOMA-IR) daha yüksek (p=0,149) ve HDL düzeyi daha düĢük (p= 0,292) idi. Plazma GLP-1 seviyesi, serum glikoz konsantrasyonu ile pozitif (r= 0.344; p= 0.079), HDL seviyesi ile negatif korelasyon gösterdi (r= -0.128; p= 0.525). KAH olan bireyler, KAH olmayanlara göre daha düĢük plazma GLP-1 düzeyine sahipti (p= 0.334).Sonuç: Bu gözlemler, GLP-1'in MetS'un geliĢmesinde önemli bir rol oynadığını kanıtlamaktadır. Elde edilen sonuçlar, MetS tedavisi için inkretin temelli tedavilere yeni bakıĢlar sağlayacaktır
Objective: The metabolic syndrome (MetS) is a cluster of metabolic disorders including, elevated fasting plasma glucose, abdominal obesity, elevated blood pressure, high serum triglycerides and low high-density lipoprotein (HDL) levels. It increases risk of cardiovascular disease and premature mortality. Incretin hormones specifically GLP-1 are secreted from gut in response to food ingestion and enhance insulin secretion. GLP-1 also have multifactorial effects on food intake, blood pressure, and lipid metabolism. The aim of this study was to investigate the relationship between serum GLP-1 hormone with criteria for MetS.Material and methods: In this study, twenty-seven patients who underwent coronary angiography were included. Anthropometric measurements such as body mass index (BMI) and other required data were collected by questionnaires. Glucose, insulin, cholesterol, triglyceride, HDL and low-density lipoprotein (LDL) levels in serum samples were measured with using autoanalyzer. Measurement of plasma GLP-1 concentration done with ELISA method. Statistical analysis was performed using SPSS software.Results: Insulin resistance index (HOMA-IR) was higher (p= 0.149) and HDL level was lower (p= 0.292) in patients whose BMI ≥ 30 kg/ m2 compared with the patients whose BMI < 30 kg/ m2. Plasma GLP-1 level was positively correlated with serum glucose concentration (r= 0.344; p= 0.079), and was negatively correlated with HDL level (r= -0.128; p= 0.525). Individuals with CAD had lower plasma GLP-1 level than who did not have CAD (p= 0.334).Conclusion: These observations prove that GLP-1 play an important role in development of MetS. The results may provide new insights for incretin-based treatments for MetS
Objective: The metabolic syndrome (MetS) is a cluster of metabolic disorders including, elevated fasting plasma glucose, abdominal obesity, elevated blood pressure, high serum triglycerides and low high-density lipoprotein (HDL) levels. It increases risk of cardiovascular disease and premature mortality. Incretin hormones specifically GLP-1 are secreted from gut in response to food ingestion and enhance insulin secretion. GLP-1 also have multifactorial effects on food intake, blood pressure, and lipid metabolism. The aim of this study was to investigate the relationship between serum GLP-1 hormone with criteria for MetS.Material and methods: In this study, twenty-seven patients who underwent coronary angiography were included. Anthropometric measurements such as body mass index (BMI) and other required data were collected by questionnaires. Glucose, insulin, cholesterol, triglyceride, HDL and low-density lipoprotein (LDL) levels in serum samples were measured with using autoanalyzer. Measurement of plasma GLP-1 concentration done with ELISA method. Statistical analysis was performed using SPSS software.Results: Insulin resistance index (HOMA-IR) was higher (p= 0.149) and HDL level was lower (p= 0.292) in patients whose BMI ≥ 30 kg/ m2 compared with the patients whose BMI < 30 kg/ m2. Plasma GLP-1 level was positively correlated with serum glucose concentration (r= 0.344; p= 0.079), and was negatively correlated with HDL level (r= -0.128; p= 0.525). Individuals with CAD had lower plasma GLP-1 level than who did not have CAD (p= 0.334).Conclusion: These observations prove that GLP-1 play an important role in development of MetS. The results may provide new insights for incretin-based treatments for MetS